title: Dual targeting biomimetic liposomes for paclitaxel/DNA combination cancer treatment.
abstract: Combinations of chemotherapeutic drugs with nucleic acid has shown great promise in cancer therapy. In the present study, paclitaxel (PTX) and DNA were co-loaded in the hyaluronic acid (HA) and folate (FA)-modified liposomes (HA/FA/PPD), to obtain the dual targeting biomimetic nanovector. The prepared HA/FA/PPD exhibited nanosized structure and narrow size distributions (247.4 ± 4.2 nm) with appropriate negative charge of -25.40 ± 2.7 mV. HA/FA/PD (PTX free HA/FA/PPD) showed almost no toxicity on murine malignant melanoma cell line (B16) and human hepatocellular carcinoma cell line (HepG2) (higher than 80% cell viability), demonstrating the safety of the blank nanovector. In comparison with the FA-modified PTX/DNA co-loaded liposomes (FA/PPD), HA/FA/PPD showed significant superiority in protecting the nanoparticles from aggregation in the presence of plasma and degradation by DNase I. Moreover, HA/FA/PPD could also significantly improve the transfection efficiency and cellular internalization rates on B16 cells comparing to that of FA/PPD (p < 0.05) and PPD (p < 0.01), demonstrating the great advantages of dual targeting properties. Furthermore, fluorescence microscope and flow cytometry results showed that PTX and DNA could be effectively co-delivered into the same tumor cell via HA/FA/PPD, contributing to PTX/DNA combination cancer treatment. In conclusion, the obtained HA/FA/PPD in the study could effectively target tumor cells, enhance transfection efficiency and subsequently achieve the co-delivery of PTX and DNA, displaying great potential for optimal combination therapy.
authors.affiliation: Department of Clinical Lab, Jinan Stomatological Hospital, Jinan 250001, China. runrun20070606@sina.com.
authors.forename: Guo-Xia
authors.initials: GX
authors.lastname: Liu
authors.affiliation: Department of Clinical Lab, Jinan Stomatological Hospital, Jinan 250001, China. fangguiqing123@126.com.
authors.forename: Gui-Qing
authors.initials: GQ
authors.lastname: Fang
authors.affiliation: Department of Pharmacy, Shandong Provincial Qian Foshan Hospital, Jinan 250014, China. 13964016747@126.com.
authors.forename: Wei
authors.initials: W
authors.lastname: Xu
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry* / Q000633:toxicity; D032701:Biomimetics; D002470:Cell Survival; D004247:DNA / Q000737:chemistry*; D003850:Deoxyribonuclease I / Q000378:metabolism; D004355:Drug Stability; D005492:Folic Acid / Q000737:chemistry; D056945:Hep G2 Cells; D006801:Humans; D006820:Hyaluronic Acid / Q000737:chemistry; D008081:Liposomes / Q000737:chemistry; D051379:Mice; D053758:Nanoparticles / Q000737:chemistry*; D017239:Paclitaxel / Q000737:chemistry* / Q000633:toxicity; D055672:Static Electricity
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D008081:Liposomes; D006820:Hyaluronic Acid; D004247:DNA; D005492:Folic Acid; D003850:Deoxyribonuclease I; D017239:Paclitaxel